ExSight Ventures has invested in DefEYE, a company specializing in the development of decellularized placental-based biologic solutions for ocular care. The funding supports DefEYE’s efforts to commercialize its technology and expand its portfolio aimed at improving outcomes in both ocular surface disease management and surgical procedures.
DefEYE has positioned itself within the ocular biologics sector by delivering tissue-based therapies designed to support treatment in conditions such as ocular surface diseases and pterygium surgery. The company’s approach centers on utilizing decellularized tissue to enhance patient comfort, accelerate recovery, and improve long-term therapeutic outcomes.
The investment from ExSight is expected to accelerate DefEYE’s commercialization strategy as it works to expand clinical adoption across ophthalmic practices. The interest from ExSight and physician advisors reflects growing validation from clinicians who have examined the technology in practice and observed positive patient responses.
DefEYE’s leadership notes the strategic alignment between the two organizations, citing ExSight’s track record of supporting technologies that advance the standard of care in ophthalmology.
KEY QUOTES
“ExSight’s investment defies our initial skepticism of the technology and the market. We were introduced to DefEYE’s CEO through a trusted advisor, friend, and colleague. Continued conversations with ExSight’s proprietary network of ophthalmologists across the nation revealed several critical factors, including better clinical outcomes, improved patient experience, and consequently, growing adoption.”
Firas Rahhal, Cofounder, ExSight Ventures
“I came to it with an equal amount of skepticism. What I immediately noticed was that I was getting clinical outcomes just as good — if not faster — and patients were far more comfortable.”
Neel Desai, MD
“We work hard to find exceptional, driven, dynamic entrepreneurs at ExSight Ventures. Dr. Sambursky embodies those traits. We are happy to back Rob and DefEYE’s portfolio of decellularized biologics for the eye.”
Dr. Michael Nissen, Cofounder, ExSight Ventures
“ExSight Ventures’ deep knowledge and long-standing commitment to advancing innovation in the ophthalmic space make them an ideal strategic partner for DefEYE. Their investment represents a strong validation of our vision to redefine ocular biologics through decellularized placental-based technology. Together, we are positioned to accelerate the adoption of regenerative therapies that elevate the clinical management of both ocular surface disease and ocular surgery.”
Rob Sambursky, MD, Chief Executive Officer, DefEYE
